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Mutacin 1140, a class 1 bacteriocin, is produced by Streptococcus mutans and
belongs to the type A lantibiotic family. Experiments were done to optimize production
of mutacin 1140 in minimal media enabling a more cost efficient downstream
purification method. The development of a small volume fermentation method enabled a
rapid screen of several variables in a standard shaking incubator. This method provided a
fast approach for determining components that promote mutacin 1140 production in
minimal media broth. Lactose was determined to be the optimal carbon source for
mutacin 1140 production. High concentrations of CaCl2 (0.3% w/v) and MgSO4 (0.77%
w/v) promoted an increase in mutacin 1140 production, while ZnCl2 and FeCl3 appeared
to impair production. Optimization of mutacin 1140 production in minimal media
resulted in more than a 100-fold increase in production compared to the base medium
used to begin our optimizations. The yield has been estimated by RP-HPLC to be 10
mg/L.
Key words: Mutacin 1140, Lantibiotic, Streptococcus mutans, fermentation, minimal
medi
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CHAPTER I
INTRODUCTION

Today’s world is facing a problem of bacterial antibiotic resistance. To solve this
problem it is necessary to find new and better antimicrobial substances. A large body of
research and investigation has been going on over the past few decades for new
antimicrobials with novel mechanisms of action. Bacteriocins are a group of antibiotics
which are proteinaceous in nature [1]. There are different kinds of bacteriocins which
have been characterized to date and among them Class I are characterized by being small
peptide inhibitors containing modified residues. Class II are characteristically larger,
approximately 40 amino acids, and the mechanism of action is generally by disrupting
bacterial membranes. These two classes of bacteriocins are most studied due to their
abundance and their potential use for industrial applications [2]. Of interest are
bacteriocins produced by Streptococcus mutans which are known as mutacins [3]; in
particular, a class I bacteriocin called mutacin 1140 (Figure 1). Mutacin 1140 belongs to
a subgroup of class I bacteriocins called lantibiotics. Lantibiotics are defined as
lanthionine-containing antibacterial peptides with dehydrated amino acid residues and
thioether bridges resulting from posttranslational modifications [1,4]. The term lantibiotic
comes from the presence of unusual amino acids called lanthionine (Lan) and Eethyllanthionine (MeLan) (Figure 2). In addition to Lan and MeLan residues, there
areother modified amino acids found in mutacin 1140 which include 2,31

didehydroalanine (Dha), 2,3 didehydrobutyrine (Dhb), and the unsaturated lanthionine
derivatives such as S-amino vinyl-D-cysteine (AviCys). Mutacin 1140 is composed of
four lanthionine rings. The C-terminal lanthionine rings C and D overlap, which adds to
the complexity of the structure of this antimicrobial peptide.

Figure 1. Covalent structure of mutacin 1140 [5].

Figure 2. Diagram of the modified amino acid residues present in mutacin 1140[5].

There are two groups of lantibiotics: Type A and Type B, which are grouped
based on their structural and functional features. Type A lantibiotics are elongated,
cationic peptides up to 34 residues in length. Type A lantibiotics which include nisin,
gallidermin, epidermin, and mutacin 1140 act by disrupting the membrane integrity of
target organism via a specific interaction to the membrane component lipid II [6-23].
Type B lantibiotics, such as actagardine, are globular peptides containing up to 19
2

residues in length. They act through disrupting enzyme function e.g., inhibition of cell
wall biosynthesis [24,25].
A series of enzymes act on a ribosomally synthesized prepeptide to produce a
mature lantibiotic molecule (Figure 3, Step1) [5]. In mutacin 1140, mutA gene (LanA
gene) encodes a ribosomally synthesized prepeptide containing serine and threonine
residues. The mutB enzyme (LanB) is responsible for the dehydration of the serine and
threonine residues to give Dha and Dhb, respectively. Cysteine residues located upstream
of the dehydrated residues form a thioether linkage to these dehydrated amino acids [5].
MutC enzyme (LanC) is responsible for the subsequent addition of cysteine sulfhydryl
groups to the didehydro amino acids, which results in the thioether ring formations
(Figure 3, Step 2). The mutD enzyme (LanD) catalyzes the oxidative decarboxylation of
the C-terminal cysteine, which gives a C-terminal S-aminovinyl-D-cysteine (AviCys)
residue (Figure 3, Step 2). MutT (LanT), an ABC transporter, transports the modified
peptide outside of the cell where mutP (LanP) an extracellular protease cleaves the leader
sequence of the modified prepeptide (Figure 3, Step 3) [5].

3

Figure 3. Diagram of the enzymatic modification taking place for mature mutacin 1140
production [5].

Mutacin 1140 has significant commercial value and broad applicability and
practical methods for its production would have a significant economic impact. Mutacin
1140 has activity against essentially all tested Gram-positive bacteria and in particular
certain medically important Gram-positive bacteria such as Staphylococcus aureus,
Streptococcus pneumonia, Enterococcus faecalis and Listeria monocytogenes. Mutacin
1140 has also been shown to have potential oral applications for fighting tooth decay and
is a key feature in the development of replacement therapy [26-29]. The producing strain
of mutacin 1140, S. mutans JH1140, was engineered to make alcohol instead of lactic
acid, which prevents the bacterium’s ability to erode tooth enamel, thus preventing the
formation of cavities. This strain has been shown to displace disease-causing strains of S.
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mutans from the teeth of experimental animals due to its ability to produce mutacin 1140,
and thereby indicating possible life-long protection against tooth decay [27,28].
As mentioned above mutacin 1140 has been shown to have desirable
characteristics for the treatment of Gram positive infections [28,30]. The principal reason
that compounds like mutacin 1140 have not been developed for therapeutic applications
is due to the general difficulty of obtaining these molecules in sufficient, cost effective
amounts to enable their testing and commercialization. Of the lantibiotics characterized
to date [1], only the Type A (I) lantibiotic nisin A, produced by Lactococcus lactis has
found wide application as a food preservative for the past 50 years. It is important to note
that the bacterium L. lactis produces nisin A when used as a starter culture and the
antibiotic itself has never been purified and directly added as a preservative. Fairly
recently, a purification protocol for nisin A has been filed as a US patent application
(USPA 20040072333), which utilized a cocktail of expensive proteases followed by
column chromatography. There is no published, commercially viable procedure for the
purification of nisin A. The problem of finding a commercially viable procedure for
purifying nisin A is also true for mutacin 1140, as well as many other lantibiotics.
Fermentations have been optimized for the lantibiotics gallidermin and mutacin
NY266 using complex media, such as yeast extract, high (5%) calcium chloride
concentrations and using a large inoculum (10% v/v). These authors have reported
production levels over 200 mg/L [31-35]. Using similar conditions and media
composition about 50 mg/L of mutacin 1140 in a 3L bioreactor controlling temperature,
pH, and oxygen is achievable [36]. Extraction of mutacin 1140 from this complex
medium by RP-HPLC methods is also achievable, but not a commercially viable
5

approach because of the high cost for the purification. Synthetic approaches to making
lantibiotics is extremely costly involving more than 60 chemical steps [37]. A semisynthetic approach for producing nisin has been described, in which cell and membrane
extracts recovered from the nisin producing organism are mixed with nisin prepropeptide
made by an E. coli expression system [38]. However, the yield of antibiotic produced by
this approach is very low. This research will attempt to identify components important for
the production of mutacin 1140 in a minimal medium, which will enable future studies
aimed at developing a cost effective approach to purifying the mutacin 1140.
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CHAPTER II
METHODS AND MATERIALS

All media was purchased from Difco Laboratory (Detroit, MI) and chemicals
were purchased from Fisher Scientific (Pittsburgh, PA) and were the highest grade,
unless otherwise stated.

Bacterial Strains
Bacterial strains used in this study include: Streptococcus mutans JH1140 ATCC
55676 and Micrococcus luteus ATCC 272. S. mutans was used for the production of
mutacin 1140. M. luteus was used as an indicator organism for detection of mutacin 1140
production.
S. mutans was first screened for colonies that would grow on minimal media and
maintain antimicrobial activity. Colonies of S. mutans were picked from plates grown on
Todd Hewitt-yeast extract (30 g Todd Hewitt broth/L, 3 g yeast extract/L) and plated on
modified M9 agar (M9 medium, supplemented with casamino acids (10 g/L), CaCl2 (5
g/L), glucose (40 g/L), NaHCO3 (1 g/L), and agar (15 g/L). During our initial screen of
medium components, casamino acids were determined to be essential for the
antimicrobial activity of S. mutans. Individual colonies grown on modified M9 agar were
selected and screened for antimicrobial production using a standard deferred antagonism
assay as outlined below. Colonies stabbed into a fresh modified M9 agar plate were
7

overlaid with M. luteus indicator strain, while simultaneously plating on a fresh master
plate of each colony. Ten colonies producing the largest clearing were analyzed again.
The colony that produced the largest zone was selected for further analysis. One
possibility, clearing is proportionate to mutacin 1140 production in the minimal media
environment, thus this strain was used as the inoculum in the optimization of mutacin
1140 production in minimal media.

Rapid procedure for optimizing fermentation conditions
A stock solution of 100 μL aliquots of purified mutacin 1140 (provided by
Oragenics Inc., Alachua FL) in 80% acetonitrile at a concentration of 10μg/mL was
stored at 4qC and was use to compare mutacin 1140 production over different variables
and across different samples. Small volume (20 mL) fermentations using a modified M9
minimal medium (M9 medium, supplemented with casamino acids and a 10% inoculum
of S. mutans was used as our base medium for optimizing each variable in a shaking
incubator at 200 rpm at 37qC for 24 hours. The inoculum was started from a 400 μL
glycerol stock (109 CFU (colony forming unit)/mL) grown in 40 mL of modified minimal
media supplemented with 0.3% yeast extract (to help boost the inoculum growth rate) to
an OD600 of 0.8 at 37qC.
At completion of the fermentation, the samples were centrifuged at 23,000 x g for
20 min and then the supernatants were collected. The collected supernatants were heated
for 30 minutes at 65qC to kill any remaining bacteria. The resulting supernatant was
assayed for mutacin 1140 production using the modified deferred-antagonism assay
described below. Five microliters of the resulting supernatants were stabbed in triplicate
8

horizontally across a 100 mm Todd Hewitt-Yeast extract plate and the mutacin 1140
stock solution was also stabbed in triplicate across each bioassay plate for comparison.
Quantification of mutacin 1140 production was determined by the following formula:
Mutacin production = diameter of culture liquor zone (mm)/diameter of mutacin 1140
stock solution zone (mm). The ratio of each zone was averaged and the standard
deviation was calculated using the averaged ratios from each fermentation (n = 3). This
approach enabled the comparison of each variable tested across numerous plates.

Antimicrobial assay
A M. luteus deferred-antagonism assay is a qualitative assay for bactericidal
activity. M. luteus is a mutacin sensitive strain with a nanomolar minimum inhibitory
concentration (MIC). M. luteus was grown in Todd Hewitt-yeast extract to an OD600 of
0.2. Then, 400 μL of these cells were added to 10 mL of top agar (M9 media, casamino
acids 10 g/L, and agar 7.5 g/L). 5 ml of melted top agar containing the standardized
suspension were added to each Petri dish containing approximately 20 mL of modified
M9 media agar. Before the plates were overlaid with the top agar containing the indicator
strain, individual colonies of S. mutans were stabbed into the modified M9 medium agar
and placed inverted into a candle jar for 48 hours. Following two days of incubation, the
stabbed colonies were then overlaid with the top agar containing M. luteus. The plates
were then allowed to dry before being inverted and placed in a candle jar overnight at
37°C. The following day the plates were checked to determine the relative size of the
zone of inhibition created by the stabbed colonies. Zones of inhibitions were measured in
units of millimeters. The modified deferred antagonism assay was performed as described
9

above for the deferred antagonism assay, except that 5μL of the supernatant of the
overnight fermentations was stabbed instead of a bacteria colony into Todd Hewitt-yeast
extract agar plates and overlaid M. luteus in Todd Hewitt-yeast extract top agar (30 g
Todd Hewitt Broth/L, 3 g yeast extract/L, and 7.5 g agar/L). Once the top agar on the
Petri dish had solidified 5 μL of the cell free culture liquor was stabbed in triplicate on
the plate. The plates were then allowed to dry before being inverted and placed in a
candle jar overnight at 37°C. Zones of inhibitions were measured in units of millimeters.
Supernatants from fermentations using our base medium was used as a positive control
for mutacin 1140 production and each medium tested (minus the inoculum) was used as a
negative control for antimicrobial activity. Colony forming units (CFU) were determined
in duplicate by serial dilution and plating method. S. mutans grows in long chains, thus
the CFU data is slightly variable.

Quantification of mutacin 1140
Following optimization parameters described above, the supernatant of the culture
broth was analyzed by RP-HPLC. RP-HPLC was done using a 4.6 x 250 mm C18
column (Grace-Vydac, catalog 201TP54) on a Bio-Rad BioLogic F10 Duo Flow with
Quad Tec UV-Vis Detector system. An acetonitrile gradient was established by varying
the flow rate of Solvent A (99% acetonitrile-0.1% trifluoroacetic acid (TFA)) relative to
Solvent B (Water-0.1% TFA) maintaining a constant flow rate of 1.0 mL/min and
monitored at 220 nm. RP-HPLC protocol following a 1 mL injection consisted of a linear
gradient (Solvent B, decreased from 95%-30% over a 30 min period), followed by an
isocratic flow (Solvent B, 95% over a 5 min period). Mutacin 1140 eluted from the
10

column at approximately 56% solvent B. Quantification of mutacin 1140 was ascertained
from peak volume. MALDI-TOF (ABI 4700 Proteomics Analyzer) was used, along with
the M. luteus modified deferred-antagonism assay, to verify the HPLC mutacin fraction.

-cyano-4-hydroxycinnamic acid was used as the matrix for MALDI-TOF. 
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CHAPTER III
RESULTS AND DISCUSSION

Determining optimal concentration of calcium chloride for mutacin 1140 production
Earlier experiments in the complex medium yeast extract showed that a high
concentration of CaCl2 (5% w/v) was optimal for mutacin 1140 production [36]. Due to
the importance of calcium chloride for mutacin 1140 production in broth, CaCl2 was the
first component optimized. To determine the optimal concentration for CaCl2, the
following percentages (w/v), 0, 0.1, 0.2, 0.3, 0.4, 0.5, 1.0, and 1.5% were first
investigated. Figure 4 presents the optimal concentration of CaCl2 for mutacin 1140
production. The black columns in the figure correspond to antimicrobial activity, while
the grey columns correspond to the CFU values. The optimal concentration for mutacin
1140 production was 0.3% CaCl2. There was approximately a 40% increase in zone
diameter as compared to 0.2 and 0.5% CaCl2. Interestingly there appeared to be a narrow
window for promoting mutacin 1140 production. No activity was observed at 0.1% and
1% CaCl2 concentrations. CaCl2 also appeared to be required for cell survival, since there
were no CFUs when calcium was inabated from the media.

Furthermore, higher

concentration of CaCl2 appeared to inhibit growth since there was an order of magnitude
drop in cell density at 1.0 and 1.5% concentration compared to 0.5%. A 0.3% CaCl2
concentration was used as our base medium for the following optimization experiments.
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Figure 4. Optimization of mutacin 1140 production by varying CaCl2 concentrations
ranging from 0.0 to 1.5 %.

Determining optimal concentration of biologically important metals for mutacin
1140 production
Several other inorganic salts can be tested for their effect on mutacin 1140
production, but for the scope of this study the inorganic salts tested were MgSO4, ZnCl2,
and FeCl3. Figure 5 presents the optimal concentration of MgSO4 for mutacin 1140
production. The black columns in the figure correspond to antimicrobial activity, while
the grey columns correspond to the CFU values. Magnesium ions are required in a
variety of enzymatic reactions, including DNA replication. Mutacin 1140 production was
absent when magnesium ions were not added (Figure 5). Interestingly, there was cellular
growth without the addition of magnesium. Presumably, the small amount of yeast
extract added to the inoculum provided a sufficient source of magnesium ions for growth.
There was an interesting decrease in mutacin 1140 production between 60 and 480
μg/mL of magnesium sulfate. These experiments were repeated showing the same
13

phenomenon. Optimal production of mutacin 1140 occurred at 7,680 μg/mL (0.77% w/v)
of MgSO4. However, the benefit of a high concentration of MgSO4 has never been
mentioned in the production of other lantibiotics. The role of zinc ions had been shown to
be important for the production of other lantibiotics [38-40]. Zinc is important for the
activity of the post translational modification enzyme responsible for the formation of the
lanthionine rings. Interestingly, mutacin 1140 production decreased when ZnCl2 was
supplemented at concentrations between 20 and 40 μg/mL (Figure 6). The Black columns
in the figure correspond to antimicrobial activity, while the grey columns correspond to
the CFU values. Given the CFUs at these concentrations, the cells appeared to be healthy
since they grew. Also of interest is that mutacin 1140 production was best when no zinc
was supplemented in the media. If zinc is a requirement for the formation of the thioether
linkages between the cysteine sulfhydryl groups and the didehydro amino acids, then
presumably a small amount of zinc may be present in the inoculum which is sufficient for
enzymatic activity. Nonetheless, supplementing with additional zinc should be avoided.
Iron ions have an important role in the catalytic sites of several bacterial enzymes.
Supplementing FeCl3 between 0 and 10 μg/mL had no effect on mutacin 1140
production, however at concentrations above 10 μg/mL, a pronounced effect on S.
mutans viability and mutacin 1140 production was observed (Figure 7). The black
columns in the figure correspond to antimicrobial activity, while the grey columns
correspond to the CFU values. It is interesting to note that there was a significant amount
of mutacin 1140 produced when the media was supplemented with 80 μg/mL given that
the cell density was >1000 fold less than the media containing no supplemented iron.
Future experiments will explore whether the addition of iron at a later time point in the
14

fermentation can promote additional mutacin 1140 production. Perhaps bacterial growth
is not an important criterion for mutacin 1140 production and that a later time period in
which there is a higher cell density may afford more mutacin 1140 production by
possibly inactivating other cellular activities that can down regulate mutacin 1140
production.

Figure 5. Optimization of mutacin 1140 production by varying MgSO4 concentrations
ranging from 0.0 to 7,680 μg/mL.

Figure 6. Optimization of mutacin 1140 production by varying ZnCl2 concentrations
ranging from 0.0 to 40 μg/mL.
15

Figure 7. Optimization of mutacin 1140 production by varying FeCl3 concentrations
ranging from 0.0 to 160 μg/mL.

Screening media supplemented with cystine
Currently, the concentration of casamino acids in the base media is 10 mg/mL.
Two amino acids, cysteine and tryptophan, do not survive the hydrolysis procedure of
casein that is used for making casamino acids. Given that four of the 22 amino acids
found in mutacin 1140 are cysteines, an experiment was designed to determine whether
the addition of cystine would have an effect on the production of mutacin 1140. Cysteine
was shown to boost the production of the lantibiotic gallidermin when supplemented in
the fermentation media [32]. The following concentrations of cystine were tested; 0
μg/mL, 100 μg/mL, 200 μg/mL, 400 μg/mL, and 800 μg/mL. The disulfide link between
the two cysteines in cystine is readily reduced by the bacterium to give the corresponding
thiol amino acid. The concentration of cystine for Mutacin 1140 production is presented
in figure 8. The black columns in the figure correspond to antimicrobial activity, while
the grey columns correspond to the CFU values. The addition of cystine to our minimal
M9 production medium had no significant effect on the production of mutacin 1140
16

(Figure 8). Possibly supplementing cystine may be important as the yield of mutacin
1140 is improved and will again be explored in future fermentations.

Figure 8. Optimization of mutacin 1140 production by varying cystine concentrations
ranging from 0.0 to 800 μg/mL.

Screening sugars for determining optimal carbon source
The base medium for the production of mutacin 1140 contains 4% glucose, which
may not be the optimal carbon source for mutacin 1140 production. Several
monosaccharide and disaccharide sugars were tested to determine the optimal carbon
source. The monosaccharides glucose, galactose, fructose, xylose and ribose, as well as
the disaccharides sucrose, maltose and lactose were tested at a 4% concentration (w/v).
Production of mutacin 1140 was enhanced with the addition of lactose and galactose.
Figure 9 presents the optimal concentration of monosaccharide and disaccharide sugars at
4% (w/v) concentrations. The black columns in the figure correspond to antimicrobial activity,
while the grey columns correspond to the CFU values. Carbon sources fructose, xylose, and

ribose resulted in no or low mutacin 1140 production, while the CFUs suggested that
these carbon sources did support growth. Optimal concentration of lactose and galactose
17

in the fermentation media was not possible to determine because of the present scope of
the research.

Figure 9. Optimization of mutacin 1140 production by varying monosaccharide and
disaccharide sugars at 4% (w/v) concentrations.
Determining optimal temperature and time for mutacin 1140 production
Mutacin 1140 production was tested at 37, 32, and 27qC. There was minimal
production of mutacin 1140 at 32 and 27qC over a 24 hour time period (data not shown).
Therefore, fermentations at 37qC using the modified M9 minimal media appeared to be
the optimal temperature for determining the effects that the other variables had on
mutacin 1140 production. Temperatures between 37 and 32qC as well as higher
temperatures were considered for future experiments. There was no difference in mutacin
1140 production between the 24 hour and 48 hour samples at 37qC, which suggests that
mutacin 1140 was produced during the 24 hour time period after inoculation. Samples
were drawn hourly over a 24 hour time period to determine mutacin 1140 production
(Figure 10). pH values of the fermentation broth listed in the figure was for each 2 hour
18

interval. Interestingly, there was no production until the ninth hour and production
stopped at the twelfth hour. The pH over this time period ranged from 5.3 to 4.7. It is
interesting to speculate that a lower pH is required for mutacin 1140 production. A 24
hour time period appears to be sufficient for optimizing mutacin 1140 production, since
other variables may promote a longer timeframe in which mutacin 1140 is produced and
since the compound is stable in the supernatant over 24 hours. Once mutacin 1140
production is completely optimized, scaling the time frame to peak mutacin 1140
production will be reinvestigated.

Figure 10. Production of mutacin 1140 over a 24 hour time period.
Optimized media
A fermentation at 37qC for 24 hrs using all the optimized variables in the
modified M9 media, supplemented with 1% casamino acids, 0.1% NaCOH3, 0.3% CaCl2,
0.77% MgSO4, and 4% lactose resulted in the supernatants having an antimicrobial
activitiy greater than 1.0, demonstrating that production in a shaking incubator exceeded
the concentration of the mutacin 1140 standard (10 mg/L) (data not shown). The
19

procedure was scaled from a 20 mL fermentation volume to a 500 mL fermentation
volume in a 1 L bottle, which resulted in the same level of production (Figure 11).
Translation of the procedure to 500 mL is important for future optimization studies in a
controlled bioreactor. A serial 5 fold dilution assay of the 500 mL fermentation media
also resulted in the same level of activity as was observed in the mutacin 1140 standard.
The antimicrobial activity units for each five fold dilution of the mutacin 1140 standard
and for the 500 mL fermentation are shown in Figure 11. The antimicrobial activity units
were calculated by taking the ratio of the diameter of each dilution to diameter of the first
zone of the mutacin 1140 standard. This shows that a 125 fold dilution resulted in an
antimicrobial activity of 0.36, which was comparable to the activity seen in base
modified M9 medium, containing 0.5% CaCl2 and 4% glucose. Therefore, the small
volume fermentations in a shaking incubator method for optimizing mutacin 1140
provided a rapid means of increasing the production by more than 100 fold. Confirmation
that the antimicrobial activity observed in the fermentation came from RP-HPLC
followed by MALDI mass determination. In Figure 12, the bioactive peak corresponds to
the elution profile of mutacin 1140 eluting at 56% Water:Acetonitrile and the mass of the
purified compound corresponds to the mass of mutacin 1140 which is 2266 Da.

20

Figure 11. Modified deferred-antagonism assay of the mutacin standard and the 500 mL
fermentation.

Figure 12. HPLC Chromatogram of purified mutacin 1140.
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CHAPTER IV
CONCLUSIONS AND FUTURE DIRECTIONS

Several lantibiotics have been known for decades but they have not been
extensively tested for their potential usefulness for treating infections. The principal
reason for this is due to the difficulty of obtaining these molecules in cost effective
amounts and purity that would enable their testing for the treatment of infections. One
major draw back is the use of complex medium generally used for their production,
which obstructs the development of an effective approach to extract and purify them from
the culture liquor.
Supplementations of MgSO4, CaCl2, and lactose were shown to promote mutacin
1140 production, while ZnCl2 and FeCl3 appeared to impair production. The development
of a small volume fermentation method enabled a rapid screen of several variables in a
standard shaking incubator. Future experiments are planned using a 3L bioreactor. This
will enable us to control for oxygen and pH, which should boost our current production
[31-34]. Depending on the outcome of these experiments, the minimal medium approach
may offer a significant advantage over production in complex medium yeast extract in
terms of cost, as well as facilitating a more cost effective downstream purification
method. Nevertheless, the small volume fermentation method described in this paper
provides a useful method for optimizing the production of mutacin 1140 and may also be
useful in the optimization of other antimicrobial substances. Furthermore, the current
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yields of mutacin 1140 in minimal media will enable the production of isotopically
labeled mutacin 1140 for nuclear magnetic resonance studies aimed at characterizing
mutacin 1140’s structure and interactions within bacterial mimetic membranes. Also,
production in minimal media will enable the use of an IPTG inducible S. mutans plasmid
for the production of other peptides in the mutacin 1140 producing strain S. mutans
JH1140 while taking advantage of the lantibiotic transporter and extracellular protease.
Solution and solid phase peptide synthesis is the current method of choice for producing
peptides. However, the procedure requires expensive automated equipment and reagents.
Minimal media environment for the expression of peptides in S. mutans would facilitate
isolation and purification of recombinant peptides, while taking advantage of the bacterial
system to produce the peptides of choice. Small protein/peptides, under 5000 Da, are
generally degraded in E. coli expression systems, thus, future work will be aimed at
developing the lantibiotic producing stain S. mutans JH1140 to effectively produce nonnative peptides.
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